Up to about 1 person in 100,000 in the U.S. is estimated to be diagnosed with primary cold agglutinin disease (CAD) each year and up to 3 in 10,000 people are living with the disease, a study that analyzed 2016-2023 data from national claim databases suggests. Primary CAD…
News
A 76-year-old woman with cold agglutinin disease (CAD) underwent an emergency upper endoscopy, a procedure to look at the upper gastrointestinal tract, without any disease-related complications, thanks to warming strategies that prevented her body temperature from getting too low, a study shows. Such strategies included raising the temperature of…
A man developed cold agglutinin disease (CAD) shortly after receiving a COVID-19 vaccine, which ultimately led to the diagnosis of an underlying blood cancer known as diffuse large B-cell lymphoma (DLBCL), according to a recent case report. While COVID-19 vaccines are considered safe and effective, the authors emphasized the…
Warming strategies to prevent body temperature from dropping enabled a 42-year-old woman with cold agglutinin disease (CAD) to undergo a hysterectomy under general anesthesia without any disease-related complications, a study shows. “Comprehensive strategies — including measures to promote heat production, maintain core temperature, and prevent redistributive hypothermia — are…
A middle-aged woman in Iran with a history of Raynaud’s phenomenon was found to have cold agglutinin disease (CAD) after developing blue-tinged skin, known medically as acrocyanosis, and other severe symptoms, according to a case report highlighting the importance of early diagnosis and treatment in CAD. Raynaud’s…
A 79-year-old woman developed cold agglutinin disease (CAD) secondary to a rare, aggressive type of blood cancer called intravascular large B-cell lymphoma (IVLBCL), a case study reports. B-cell lymphomas are a form of blood cancer that affects B-cells, the type of white blood cell that produces antibodies, including those that…
Cold agglutinin disease (CAD) appears to be the most common type of autoimmune hemolytic anemia (AIHA) — a group of autoimmune diseases marked by attacks on red blood cells — that is triggered by COVID-19, according to a review of published studies. Patients developed AIHA about 13 days after…
Riliprubart (SAR445088), a potential successor to Enjaymo (sutimlimab-jome) as a cold agglutinin disease (CAD) treatment, may achieve therapeutic levels with every-three-month dosing at a fixed dose. That’s according to a study that used modeling tools to analyze available clinical trial data and propose an optimal dosing regimen for…
Nearly half of people without symptoms of cold agglutinin disease (CAD) who undergo a lung transplant test positive for cold agglutinins, the self-reactive antibodies that drive the rare autoimmune condition by targeting red blood cells at low temperatures. That’s according to new data from the first study of its kind…
A 12-year-old girl in Italy developed cold agglutinin disease (CAD) as a result of an infection with the Epstein-Barr virus (EBV), the virus that causes infectious mononucleosis, a case study reported. Treatment with the corticosteroid methylprednisolone and intravenous immunoglobin (IVIG) progressively led to complete resolution of her CAD symptoms.
Recent Posts
- Post-exertional malaise leads to a cycle of crashes and comebacks
- Enjaymo provides lasting CAD control even with fewer doses: Study
- Being vigilant during transfusions brings me a vital victory
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD
- With my health from CAD steadily declining, I call in the cavalry, part 2
- FDA fast-tracks potential new option for autoimmune blood diseases
- Long-term Enjaymo use shows favorable outcomes in CAD: Study